|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1997-2-25
|
|
pubmed:abstractText |
The purpose of the study is to compare the efficacy and safety profile of 2.0% dorzolamide (three times daily) and 0.5% timolol (twice daily) for up to 6 months in patients with glaucoma or ocular hypertension associated with pseudoexfoliation. The additive effects of dorzolamide and timolol in patients requiring add-on therapy also was evaluated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0161-6420
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
137-42
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9022118-Adrenergic beta-Antagonists,
pubmed-meshheading:9022118-Adult,
pubmed-meshheading:9022118-Aged,
pubmed-meshheading:9022118-Aged, 80 and over,
pubmed-meshheading:9022118-Carbonic Anhydrase Inhibitors,
pubmed-meshheading:9022118-Double-Blind Method,
pubmed-meshheading:9022118-Drug Therapy, Combination,
pubmed-meshheading:9022118-Exfoliation Syndrome,
pubmed-meshheading:9022118-Female,
pubmed-meshheading:9022118-Glaucoma,
pubmed-meshheading:9022118-Humans,
pubmed-meshheading:9022118-Intraocular Pressure,
pubmed-meshheading:9022118-Male,
pubmed-meshheading:9022118-Middle Aged,
pubmed-meshheading:9022118-Ocular Hypertension,
pubmed-meshheading:9022118-Ophthalmic Solutions,
pubmed-meshheading:9022118-Sulfonamides,
pubmed-meshheading:9022118-Thiophenes,
pubmed-meshheading:9022118-Timolol
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension.
|
|
pubmed:affiliation |
Malmö University Hospital, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|
